BACKGROUND: Gentamicin and vancomycin are commonly used in neonatal units for the treatment of life-threatening infections. This study aimed to describe the dosage regimen and the approach to therapeutic drug monitoring (TDM) for both antibiotics in units that participate in a UK neonatal network. METHODS: Questionnaires were sent to all units across the Extended Neonatal Network, requesting details of each unit's dosing regimen and TDM practice. RESULTS: A total of 43 (of 114) units replied to the gentamicin questionnaire and 29 to the vancomycin questionnaire. Ten different gentamicin dosing regimens were used, depending on gestational age and weight. Most units (79%) followed British National Formulary for Children dosing guidance regarding vancomycin, but there were nine variations in TDM practice. CONCLUSIONS: There is significant variation in gentamicin and vancomycin dosing regimens and TDM guidance across a UK network of neonatal units. The development of standardized, evidence-based protocols should be prioritized.
BACKGROUND:Gentamicin and vancomycin are commonly used in neonatal units for the treatment of life-threatening infections. This study aimed to describe the dosage regimen and the approach to therapeutic drug monitoring (TDM) for both antibiotics in units that participate in a UK neonatal network. METHODS: Questionnaires were sent to all units across the Extended Neonatal Network, requesting details of each unit's dosing regimen and TDM practice. RESULTS: A total of 43 (of 114) units replied to the gentamicin questionnaire and 29 to the vancomycin questionnaire. Ten different gentamicin dosing regimens were used, depending on gestational age and weight. Most units (79%) followed British National Formulary for Children dosing guidance regarding vancomycin, but there were nine variations in TDM practice. CONCLUSIONS: There is significant variation in gentamicin and vancomycin dosing regimens and TDM guidance across a UK network of neonatal units. The development of standardized, evidence-based protocols should be prioritized.
Authors: Anouk van der Veen; Annemie Somers; Sophie Vanhaesebrouck; Rob Ter Heine; Roger Brüggemann; Karel Allegaert; Pieter De Cock Journal: Int J Clin Pharm Date: 2021-11-02
Authors: Chris Stockmann; Michael G Spigarelli; Sarah C Campbell; Jonathan E Constance; Joshua D Courter; Emily A Thorell; Jared Olson; Catherine M T Sherwin Journal: Paediatr Drugs Date: 2014-02 Impact factor: 3.022
Authors: Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin Journal: Clin Pharmacokinet Date: 2014-07 Impact factor: 6.447
Authors: Tuuli Metsvaht; Georgi Nellis; Heili Varendi; Anthony J Nunn; Susan Graham; Andre Rieutord; Thomas Storme; James McElnay; Hussain Mulla; Mark A Turner; Irja Lutsar Journal: BMC Pediatr Date: 2015-04-16 Impact factor: 2.125
Authors: Louise F Hill; Mark A Turner; Irja Lutsar; Paul T Heath; Pollyanna Hardy; Louise Linsell; Evelyne Jacqz-Aigrain; Emmanuel Roilides; Mike Sharland Journal: Trials Date: 2020-04-15 Impact factor: 2.279